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INTRODUCTION
Urinary incontinence is defined as any ''complaint of involuntary loss of urine'' by the International Continence Society and the International Urogynecological Association. 1 Although common among women, its prevalence varies, from 13.1% to 70.9% in different populations, and the most prevalent type is stress urinary incontinence (SUI) that is, leakage when coughing, sneezing, or upon exertion. 2 Urinary incontinence may affect Quality of Life (QoL). The level of distress depends on the frequency, the amount of leakage, and on the subjective experience of these symptoms. For example, fear of leakage or of the associated odour might lead to social withdrawal. Therefore, the initial assessment and the evaluation of treatment should include both symptom severity and QoL. 3, 4 Views might differ between patients and clinicians. Thus, it is important to include reports of QoL and symptom severity directly from the patient. These reports can be collected in a standardized manner with validated self-assessment questionnaires. Of these questionnaires, many that are currently in use are highly recommended. 4 However, the diversity of questionnaires used in research and clinical practice makes it difficult to compare studies and treatments. 5 The International Consultation on Incontinence Modular Questionnaire (ICIQ) aims to promote a more uniform usage of questionnaires. 5 The ICIQ has developed and included several questionnaires in a modular structure, 5, 6 and all are highly recommended. 4 Two modules of the ICIQ are the Urinary Incontinence Short Form (ICIQ-UI SF) and the Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol); the former measures symptom severity, and the latter measures QoL. Both provide additive scores, and both have been validated in large patient groups that displayed various types of incontinence and LUTS. 5, 7 These questionnaires allow assessment of the treatment effectiveness by comparing pre-and post-treatment scores, but a given change in the overall score does not have an intuitively comprehensive meaning. 8, 9 The Patient Global Impression of Improvement (PGI-I) is an outcome measure that is readily understood by both the patient and the clinician, and it gives a direct reflection of the patient's overall opinion. It is a validated scale for the patient to rate her current (treated) condition compared to her condition prior to treatment. There are seven choices, ranging from ''very much better'' to ''very much worse. '' 8 Correlating the ICIQ-questionnaires to the PGI-I would enable a determination of the Minimum Important Difference (MID) in the overall score. The MID is the smallest reduction in the overall score that represents an improvement detected by the patient. The MID provides important information on how a change in the ICIQ questionnaire scores can be interpreted clinically.
In previous studies on men 10 and in women 11 with SUI that underwent surgical treatment, the ICIQ-UI SF correlated well to the PGI-I. A correlation was also shown between the King's Health Questionnaire (KHQ; the precursor of ICIQ-LUTSqol) and the PGI-I in women after surgical treatment for SUI. 12 However, to our knowledge, no study has correlated the ICIQ-UI SF to the PGI-I in women treated with pelvic floor muscle training (PFMT), which is the recommended first-line treatment for SUI.
13,14 Furthermore, we have not found any studies on the correlation between the ICIQ-LUTSqol and the PGI-I in either women or men with urinary incontinence.
Thus, in the present study, we aimed to investigate how a change in the overall scores from the ICIQ-UI SF and ICIQLUTSqol correlates to the PGI-I, and we aimed to establish an MID for both questionnaires in women treated with PFMT for SUI.
MATERIALS AND METHODS

Patients and Methods
We analyzed data from a recently completed randomized controlled trial (RCT), which was registered and reported at ClinicalTrials.gov (ID: NCT01032265), and described in detail by Sj€ ostr€ om et al. 15 In the RCT, 250 community-dwelling Swedish women, ages 18-70 years old, with SUI at least once a week, were enrolled in a study aimed to compare the effects of a 3-month PFMT administered either online (Internet-based programme) or by mail (postal treatment programme). The diagnosis of SUI was based on an extensive inclusion questionnaire, the ICIQ-UI SF, the ICIQ-LUTSqol, a 2-day bladder diary, and a telephone interview with an urotherapist. The first follow-up was conducted 4 months after randomisation, and it included a second completion of the ICIQ questionnaires and completion of the PGI-I. All evaluations were conducted through postal questionnaires, and we never met the women face-to-face. 15 In the present study, we only included women that had answered the PGI-I at the 4-month follow-up.
The symptom questionnaire (ICIQ-UI SF) consists of three scored questions, concerning frequency, amount of leakage, and overall inconvenience. In addition, there is a fourth, unscored diagnostic question, aimed to determine the type of urinary incontinence. The first three items renders an overall score from 0 to 21 points, where a higher score indicates greater symptom severity. The ICIQ-UI SF is considered fully validated. 5 The condition-specific QoL questionnaire (ICIQ-LUTSqol) consists of 19 items concerning different aspects of everyday life that might be affected by leakage or other bladder conditions. Each item provided four choices, which were rated 1 ¼ ''not at all''/''never,'' 2 ¼ ''slightly''/''sometimes,'' 3 ¼ ''moderately''/ ''often,'' or 4 ¼ ''a lot''/''very much''/''all the time.'' The points are summed to an overall score ranging from 19 to 76 points. A higher score indicates a larger impact on quality of life. 7 Three of the items concern personal relationships, and have an additional response: ''not applicable.'' We treated the answers as described by Sj€ ostr€ om et al.;
15 that is, the additional response was considered equivalent to no effect on this aspect of quality of life (score ¼ 1). The ICIQ-LUTSqol was derived from the validated KHQ and added to the ICIQ module, 6 with the alteration of one question and a simplification of the scoring system. It has been proven reliable in both paper and electronic formats. 16 We first calculated the overall score for both questionnaires, according to the ICIQ protocol. To save overall scores from the ICIQ-UI SF and ICIQ-LUTSqol questionnaires, as described in further detail by Sj€ ostr€ om et al., 15 missing answers were replaced at baseline with the value from the 4-month followup, and vice versa. Six ICIQ-UISF scores and 13 ICIQ-LUTSqol scores were completed in this manner. Then, we calculated the difference between the overall scores at inclusion and after treatment. In four cases for each score, it was not possible to complete the scores at follow-up and calculate the difference.
The PGI-I questionnaire consists of a single question for evaluating treatment, 8 In this study, we regarded all women as a single group, without consideration for how they were randomized in the RCT. Instead, the participants were divided into categories based on their responses to the PGI-I question. Then, the change in ICIQ-UI SF and ICIQ-LUTSqol scores between inclusion and follow-up were analyzed for each PGI-I category to determine the association.
Statistics
We calculated the Spearman rank correlation between the ICIQ-UI SF and PGI-I and between the ICIQ-LUTSqol and PGI-I. Values between 0.4 and 0.6 were considered a moderate correlation. 17 No participants considered themselves ''Very much worse'' after treatment. Only one participant answered ''Much worse;'' this participant was added to the group that responded ''a little worse'' on the PGI-I, and together, they formed the group that we referred to as ''worse.'' This combined group was used in all ANOVAs, but not in the Spearman analyses.
We performed one-way ANOVAs to determine whether the mean scores at inclusion and the mean post-treatment reductions in scores on the ICIQ-UI SF and ICIQ-LUTSqol were significantly different between different PGI-I categories. We used the Welch test when there was a significant difference in homogeneity of variance between groups. Post-hoc analyses were performed according to Tukey. We also used median reductions and quartiles to illustrate the reduction within each category.
We used an anchor-based method to establish the MID; that is, we calculated a mean ICIQ score for the participants that responded ''a little better'' on the PGI-I, and we took that mean to reflect the smallest difference detected by the patient. The group that reported ''no change'' on the PGI-I had ICIQ means higher than 0, perhaps as a result of being in a study. Thus, we also calculated the difference between the ICIQ means from the groups that responded ''a little better'' and ''no change'' on the PGI-I. This difference provided an MID for comparing one treatment to another (between-treatment MID). 18, 19 All statistical analyses were performed with SPSS version 21.0 software. The groups were considered to differ significantly from each other when P < 0.05.
Ethics
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RESULTS
At the 4-month follow-up, 218 women completed the PGI-I questionnaire and were included in this study. Four of these did not complete ICIQ-UI SF and four had no data on ICIQ-LUTSqol. The age ranged from 23 to 70 years old, with a mean age of 49.2 years. More than half of the women had completed three or more years of university studies. The women resided all over Sweden, two-thirds in urban areas and one-third in rural areas. Of the participants, 39.0% experienced daily leakage. Baseline data are summarized in Table I .
According to the PGI-I at follow-up, 83.0% of participants considered their condition improved, 14.7% unchanged, and 2.3% deteriorated. The women were categorized into five groups according to their PGI-I response (Table II) .
ICIQ-UI SF
The mean overall score on the ICIQ-UI SF was 10.20 (SD 3.71) at baseline. These mean scores were not significantly different among the different PGI-I groups (PGI-I groups determined later; Table II) .
At follow-up, the mean reduction in the overall score was 3.10 (SD 3.20). Table III summarizes the means for each PGI-I category.
We found a moderate correlation between the change in ICIQ-UI SF score and the PGI-I. The Spearman rank correlation coefficient was 0.547 (P < 0.001); thus, the larger the reduction in score, the greater the improvement experienced by the patient.
Also according to the ANOVA, the larger reduction of overall score the women had, the larger improvement they reported (P < 0.001). There were significant differences in mean overall scores among the different PGI-I categories, except between the categories ''no change'' and ''a little/much worse.'' Figure 1 shows the distribution and the median reduction within each PGI-I category. The MID (i.e., the mean change for the category ''a little better'') was 2.52 (SD 2.56). The difference between the mean changes in overall score for the groups ''a little better'' and ''no change'' was 1.58 (between-treatment MID).
ICIQ-LUTSqol
At baseline, the mean overall score for ICIQ-LUTSqol was 33.13 (SD 7.30). The baseline impact on QoL of women in the ''very much better'' group was significantly greater than of the group that experienced ''no change'' (P ¼ 0.017), but there were no significant differences among the other groups (Table II) .
At the 4-month follow-up, the mean reduction in the overall score was 4.65 (SD 6.33). There was a moderate correlation between the change in the ICIQ-LUTSqol score and the PGI-I. The Spearman rho was 0.520 (P < 0.001).
Again, the women that reported large improvements on the PGI-I questionnaire also exhibited large reductions in overall QoL score (P < 0.001). The mean change in ICIQ-LUTSqol scores differed significantly between all PGI-categories, except between the categories ''no change'' and ''a little/much worse'' (Table III) . Also here, the median reductions in score displayed the same pattern as the mean reductions in score. Figure 1 shows the variation in the median reduction in ICIQ-LUTSqol score for each PGI-I category.
The MID for the ICIQ-LUTSqol was 3.71 (SD 4.95). The difference between the mean changes in overall score for the groups ''a little better'' and ''no change'' was 3.00 (betweentreatment MID).
DISCUSSION
In this study, we demonstrated that the mean changes in overall scores on two questionnaires that measure symptom severity (ICIQ-UI SF) and quality of life (ICIQ-LUTSqol) correlates with the PGI-I as outcome measures. Larger reductions in the overall symptom and quality of life scores were associated with greater improvements (PGI-I) experienced after treatment. At the group level, the minimum reduction in overall score that could be detected was 2.52 for the ICIQ-UI SF and 3.71 for the ICIQ-LUTSqol.
A major strength of this study was the clinical relevance of the setting. All women had SUI, the most common type of UI, 2 they actively sought treatment, and PFMT is the recommended first-line treatment. 13, 14 Other strengths were that the highly recommended ICIQ questionnaires 4 and the PGI-I questionnaire are validated, 5, 7, 8 user-friendly, and used increasingly in current research. The participants completed the questionnaires in their own homes, both at baseline and at follow-up, and there were few missing data.
One limitation was that the lack of face-to-face-treatment did not resemble the most common clinical situation today. However, there is a need for new methods of delivering nonpharmacological treatments.
14 Studies have shown that Internet-based treatments increase access to care 20 and might lower the barrier for seeking care. 21, 22 Internet-based treatments are therefore likely to increase in the future. Another possible weakness was that our study population was fairly welleducated compared to the general population. Among our participants, 74.8% had completed university studies, compared with only 42.4% in the general Swedish population of women aged 23-70 years. 23 This may have affected our results in several ways. Higher socioeconomic status, indicated by education, is reported to yield lower satisfaction with treatment; 24 on the other hand, neither higher nor lower educational status has been associated with higher success rates on the PGI-I. 25 In this study, the mean changes in overall scores for the ICIQ-UI SF and ICIQ-LUTSqol correlated to the PGI-I outcome (r ¼ 0.547 and r ¼ 0.520) in women with SUI treated with PFMT. This was consistent with findings from Twiss et al. for the ICIQ-UI SF in men after a perneal sling operation. 10 The correlation we found between ICIQ-LUTSqol and PGI-I was similar in strength to the correlation found by Abdel-fattah et al. between the KHQ and the PGI-I (r ¼ 0.48) in women with SUI after surgical treatment. 12 These moderate correlations further supported the need for assessing both symptom severity and QoL to achieve comprehensive evaluations. We demonstrated a lower MID (2.5) for the ICIQ-UI SF than Sirls et al., who established MIDs of five and four points of reduction measured at 12 and 24 months, respectively, after a surgical treatment for SUI in women. 11 These results indicate that MID changes over time. The 4-month time frame applied in our study was the same used to validate the PGI-I. 8 However, MIDs might also vary, depending on the goals of the patient and of the caregiver, the pre-treatment scores, the complexity of treatment, and the anchor for the comparison. 18, 19 Compared to the participants of our study, the surgical cohort in the Sirls et al. study had higher preoperative scores, larger reductions after treatment, 11 and most likely, different expectations of the treatment. It is reasonable to believe that women expect a better outcome from an invasive treatment with greater risk of harm than from a conservative treatment.
MIDs can be used as an aid to interpret the outcome of the questionnaires after treatment. Thus, for a treatment to be considered clinically relevant, a statistically significant posttreatment improvement in the overall score should exceed the MID. Furthermore, when comparing the effects of different treatments, a statistically significant difference cannot be considered equivalent to a clinically noticeable difference. Some researchers have argued that a between-treatment MID should be used to compare treatments. This would be calculated as the difference in scores between the categories of ''a little better'' and ''no change. '' 18,19 This approach appears to be reasonable, and each researcher and clinician should consider which MID is the most appropriate for their setting.
Reports directly from the patient are important in patientcentred care, particularly in a condition like SUI, where the subjective experience of symptoms affects the QoL. Our results strengthened the position that the ICIQ-UI SF and ICIQ-LUTSqol questionnaires measure clinically relevant improvements. More research is needed to further validate MIDs in larger cohorts and in different populations. Nevertheless, in studies of women with SUI treated non-surgically, the MIDs we established could facilitate further research, evaluations of treatments, and comparisons between studies.
CONCLUSIONS
This study demonstrated that the symptoms and Qol scores, ICIQ-UISF and ICIQ-LUTSqol, respectively, measured improvements that were clinically relevant in women with stress urinary incontinence treated with pelvic floor muscle training. Our results suggested that, at the group level, overall score reductions of 2.5 and 3.7, respectively, should be considered clinically relevant.
